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CHALLENGES IN CLINICAL BATCHES
PRODUCTION OF MALARIA VACCINES
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PRE-ERYTHROCYTIC
CS, CS-RTSS, TRAP, LSA1, 
LSA3, LSA5, multi-epitopes
ASEXUAL BLOOD STAGE
SP166, MSP1, MSP2, MSP3, 
GLURP, EBA 175, AMA1, LSA3, 
Malaria Antigens developed by EVI (in red) since 
1998, and their target stage
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STARP, Exp-1, D13, PfPEBS, 
P27A
PREGNANCY ASSOCIATED






– MSP3, GLURP, P27A, PfPEBS
• Recombinant proteins:
– Lactococcus lactis (GMZ2, MSP3)
– Pichia pastoris (AMA1, AMA1 DiCo)
– E. coli (MSP1, EBA175, Pf45/48)
– Pseudomonas fluorescens (VAR2-CSA)










• Involved in erythrocyte invasion 
• Ranks as top vaccine candidate but low priority due to 
antigenic diversity




• Pichia pastoris fermentation 






• Excipientation and mixing
of  the three DiCos





Dilution, mixing & Lyophilisation
Pf AMA1 DiCo
Manufacturing challenges: stability
•  Degradation during fermentation and after
capture step (IMAC)
– Sudden onset in some batches






How was it solved:
– Lower Cu-Co concentration in the medium
– Nitrogen feed at induction
– Shorter process: 
• Moderate cell density at induction (220g/L FCW)
• Shorter induction: <20H ±2H
– On-line methanol control (in-situ probe)
•  Improvement in product quality at cost of  
accumulation level in supernatant
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Pf AMA1 DiCo
Result: purified lyophilised product stable long 




•  Aggregation and dimerisation
– Dimerisation during storage of  DS (liquid form)






Conclusion: the drug substance is stable in the 






Aggregation during lyophilisation: how was it
solved?
• Lyoprotector addition (sucrose)
• No nitrogen gassing during the formulation




• Monomer content 
>96% in DP, similar
to DS
• Dimer content < 2%, 
similar to DS
• Aggregate content 
<0.5%




• Rely on small, flexible, experienced, technology
and science driven DS and DP CMOs
• Maintain good communication and project
management (critical for virtual operations)
• Define realistic timelines (compromise on time vs 
quality and costs / critical path to the clinic)
• Avoid lyophilisation for early stage vaccines




“If  you are asking me 
anything I don’t know, 
23













Sophie Houard and colleagues at EVI
Ed Remarque/Bart Faber (BPRC)
Collaborators at IME/Fraunhofer
Collaborators at Nova Laboratories
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